Dennis J Kalota

This inventor holds 25 USPTO granted patents and 1 published patent application, plus 5 CIPO patents and 2 EPO patents, primarily in Chemical Processes. Top assignees: Monsanto Company, Solutia Incorporated, Mallinckrodt, Inc.. Active years: 1989-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dennis J Kalota. Retrieved from https://idiyas.com/inventor/dennis-j-kalota

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 1)

% Patents Active = 92.0

CIPO Patents = 5 (Patent Applications = 6)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.3

ph-index = 9

Forward Citations = 213(Granted Patents)

Company Filing History:

Years Active: 1989-2012

Loading Chart...

Areas of Expertise:

Buprenorphine Production

Opiate Alkaloids

Corrosion Inhibition

Metal Working Fluids

Microencapsulation

Polyaspartate Salts

Perfluorinated Polyethers

Anhydropolyamino Acids

Soldering

Benzylated Amines

Crystallization Methods

Polysuccinimide

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8232398 - Recycling process for increasing the yield of opiate alkaloid derivatives (2012-07-31),

2. 8232397 - Processes for the production of buprenorphine with reduced impurity formation (2012-07-31),

3. 7750187 - Crystallization method for benzphetamine (2010-07-06),

4. 7456318 - Process for preparing benzylated amines (2008-11-25),

5. 6706670 - Water soluble metal working fluids (2004-03-16),

6. 6238621 - Corrosion inhibiting compositions (2001-05-29),

7. 6228245 - Process for the preparation of tetraalkyl 1,2,3,4-butanetetracarboxylates (2001-05-08),

8. 6200499 - Compositions for corrosion inhibition of ferrous metals (2001-03-13),

9. 6020520 - Process for the preparation of tetraalkyl 1,2,3,4-butanetetracarboxylates (2000-02-01),

10. 5981761 - Crosslinked polyaspartate salts a process for their production (1999-11-09),

11. 5616544 - Water soluble metal working fluids (1997-04-01),

12. 5540927 - Microencapsulation process by coacervation (1996-07-30),

13. 5525703 - Crosslinked polyaspartic acid and salts (1996-06-11),

14. 5470942 - Preparation of anhydropolyamino acids (1995-11-28),

15. 5443651 - Process for metal cleaning (1995-08-22),

Title: Dennis J Kalota - Innovator in Opiate Production Processes

Introduction

Dennis J Kalota is a notable inventor based in Fenton, MO (US) with an impressive portfolio of 25 patents. His contributions to the field of chemical engineering and pharmaceuticals, particularly in the production of opiate alkaloids, have significantly advanced the industry.

Latest Patents

Among his latest innovations are two key patents:

1. **Processes for the Production of Buprenorphine with Reduced Impurity Formation** - This invention focuses on a method for producing buprenorphine or its derivatives while minimizing the creation of impurities.

2. **Recycling Process for Increasing the Yield of Opiate Alkaloid Derivatives** - This patent outlines a technique designed to enhance the yield of opiate alkaloids by implementing multiple recycling steps in the production process.

Career Highlights

Throughout his career, Dennis J Kalota has made substantial contributions while working at prominent companies such as Monsanto Company and Solutia Incorporated. His innovative spirit and technical expertise have positioned him as a leading figure in his field.

Collaborations

Dennis has collaborated with several accomplished professionals, including David C Silverman and John S McConaghy, Jr. These partnerships have fostered creativity and innovation, leading to advancements in the production of crucial pharmaceutical compounds.

Conclusion

Dennis J Kalota is a distinguished inventor whose work has significantly influenced the pharmaceutical industry. His commitment to innovation, combined with his technical prowess, ensures that he remains a key player in the development of new processes for opiate alkaloid production. As the landscape of pharmaceuticals evolves, his contributions will continue to be relevant and impactful.

Profile summary based on public USPTO records.